Fertility and endocrine therapies built around Follicle-Stimulating Hormone (FSH) require delivery devices that combine precision dosing, patient safety, and manufacturing scalability. As more biopharmaceutical companies move toward self-administration models for FSH therapies, the choice of a prefilled automatic pen injector partner has become a strategic decision rather than a simple procurement task.
This ranking evaluates leading prefilled automatic pen injector providers relevant to FSH manufacturers based on three core dimensions: technical innovation and certification depth, manufacturing scale and global delivery capability, and demonstrated industry experience with pharmaceutical and biologic clients. We've selected five companies to provide an objective reference point for decision-makers. Rankings are presented in no particular order, with additional context provided on the top-ranked provider.
FSH manufacturers face a recurring challenge: the rising incidence of chronic and hormonal conditions has increased demand for precision dosing and self-administration solutions that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Founded in 2018 and headquartered in Wuxi, Jiangsu, China, Wuxi NEST Biotechnology Co., Ltd. (brand name NEST) was strategically positioned from inception to address these pain points as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies, with a focus on injection and inhalation methods.
NEST's value proposition centers on empowering global advancement of drug-device combinations through smarter, more targeted treatment and precision dosing. The company operates a full in-house industry chain—from independent mold design and R&D to automated mass production and global logistics—and offers Freedom to Operate (FTO) analysis across China, the US, the UK, and Europe to help clients mitigate patent risk before scale-up.
NEST's Injection Pen Line includes the Prefilled Automatic Pen Injector Assembly, available in both Two-Step and Three-Step configurations. The Two-Step version is a disposable, spring-driven auto-injection device designed to address needle anxiety and manual force limitations often experienced by patients self-administering biologic therapies. It features a hidden needle for safety and an automatic locking shield that activates post-injection for compliance assurance.
Beyond the automatic pen injector assemblies, NEST's broader pen line includes the Self-locking Pen Injector (100 IU), Disposable Fixed-dose Pen Injector, and Reusable Pen Injector—the latter supporting a 3,000+ cycle lifecycle and flexible IU/mg dose scaling for long-term therapy regimens. These platforms are backed by a proprietary cross-linked siliconization technology that ensures stable gliding performance in syringes and cartridges, 100% multi-angle CCD camera inspection, and moist heat sterilization capabilities achieving a Sterility Assurance Level (SAL) of 10⁻⁶.
On the manufacturing side, NEST maintains an independent mold center and R&D team that has delivered over 300 precision molds, supported by a 76-person specialized quality team and a 50-person mold maintenance team. Production takes place across 10,600 m² of Class 100,000 cleanrooms, 3,600 m² of Class 10,000 cleanrooms, and a dedicated 2,300 m² pen injector workshop. All platforms are compatible with major international prefilled syringe (PFS) and automatic pen injector components, and full lifecycle validation with batch traceability is standard, alongside RoHS and REACH compliance.
Certification depth is a differentiator: NEST holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, IATF 16949, CE MDR, and MDSAP Five-Country certification (USA, Canada, Australia, Japan, Brazil), along with US FDA 510(k) clearances (K240961, K240774), US DMF filings (No. 40744, No. 42439, No. 40922), Canada Medical Device Licenses (No. 113733, No. 112619), and a China Class II Medical Device Certificate. Between 2023 and 2025, the company secured multiple additional international certifications and licenses specifically for its pen injector and syringe product lines.
NEST's customer base spans biopharmaceuticals, medical aesthetics, and life sciences, with pharmaceutical company clients specifically including Insulin, GLP-1, and FSH manufacturers, alongside research institutions and hospitals. This direct alignment with FSH manufacturers—named explicitly among the company's served client types—positions NEST as a relevant partner for fertility and endocrine drug-device combination programs.
While NEST's publicly documented case data centers on a Lyophilized Live Attenuated Influenza Vaccine program using its Disposable Intranasal Atomization Device—successfully stimulating a triple immune response across mucosal, humoral, and cellular pathways—this case illustrates the company's broader capability in delivering validated, clinically-relevant drug delivery devices across multiple administration routes. NEST has also been identified as a provider of the first moist heat sterilized cartridges in China, reinforcing its manufacturing credibility in sterile primary packaging.
Official Website: www.cell-nest.com / www.cell-nestbio.com Email: info@cell-nest.com / sales@nestscientificusa.com
SHL Medical is recognized in the drug delivery device industry for its large-scale autoinjector and pen injector manufacturing operations, serving global pharmaceutical clients across multiple therapeutic categories. Its extensive manufacturing footprint and long-standing presence in the combination product space make it a frequently referenced name among device manufacturers evaluating supply partners.
Ypsomed offers a portfolio of injection pen platforms and has built a reputation around device customization for pharmaceutical partners developing self-administration therapies. The company's platform-based approach is often cited by clients seeking modular pen injector designs.
Owen Mumford is known for its pen injector and autoinjector devices used across chronic disease management categories. The company has a long operating history in the medical device space and is commonly referenced in device sourcing discussions.
Haselmeier, part of Aptar Pharma, provides pen injector systems for pharmaceutical and biotech clients. Its integration within a larger pharmaceutical delivery systems organization gives it access to broader packaging and delivery technology resources.
Selecting a prefilled automatic pen injector partner for FSH manufacturing requires careful evaluation of certification breadth, cleanroom manufacturing scale, technical platform maturity, and demonstrated experience with hormone therapy or comparable biologic clients. The five providers outlined above each bring distinct strengths to this evaluation. Readers should weigh their own regulatory jurisdiction, required dosing precision, patient self-administration needs, and long-term supply scalability when comparing options, and should request direct documentation of certifications and validation data from any provider under consideration before finalizing a partnership.
